Long-term clinical outcomes in critical limb ischemia--A retrospective study of 181 patients by Melillo, E et al.
502
Abstract. – OBJECTIVE: Critical limb ischemia
(CLI) is the most severe manifestation of the pe-
ripheral arterial disease. To date, several prognos-
tic factors have been identified but the data of
long-term follow-up in real life setting are scarce.
The aim of our study is to describe a large group
of CLI patients and identify possible prognostic
factors, in a long-term follow-up.
PATIENTS AND METHODS: Case-control, retro-
spective study. 181 consecutive CLI patients with
a minimum follow-up of 5 years were included in
the study.
RESULTS: Overall mortality was 15%, 24%, and
43% at 1, 2, and 5 years, respectively. Among
known risk factors, only arterial hypertension
was significantly correlated with survival rate; no
differences were found between diabetics and
non-diabetics. Patients treated with intravenous
iloprost (46%), compared to untreated patients,
showed a better (p < 0.0001) long-term outcome
in terms of major amputation (6% vs. 21%), sub-
sequent vascular surgery (4% vs. 32%) and sur-
vival rates (69% vs. 47%), at 5-year follow-up. Ma-
jor amputations were significantly correlated
with lower median forefoot transcutaneous val-
ues of O2 (0/3 mmHg, p < 0.001) and higher medi-
an values of CO2 (83/53 mmHg, p < 0.0001) in
supine/dependent position, respectively. 
CONCLUSIONS: Our results confirm the poor
prognosis of CLI patients in a very long-term fol-
low-up and the severe metabolic damage caused
by ischemia. A favourable role of iloprost was
observed, in agreement with previous evidence
in the literature. 
Key words:
Critical limb ischemia, Survival rate, Major amputations,
Outcome, Transcutaneous gases measurements, Iloprost.
Introduction
Critical limb ischemia (CLI) is a major health-
care issue. Approximately 500-1000 people per
million of the population are diagnosed with
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CLI1. Peripheral artery disease (PAD) patients
present a number of typical non-modifiable (age,
sex, race) and modifiable (e.g. smoke, diabetes,
hypertension, dyslipidemia) risk factors, predis-
posing to atherosclerosis and cardiovascular dis-
ease, and have a very high risk of fatal and non-
fatal cerebro- and cardio-vascular events. Coro-
nary heart disease, assessed by coronary angiog-
raphy, is present in about 90% of patients with se-
vere PAD2.
CLI is a manifestation of both PAD and is-
chemic disease of lower limbs3. In CLI the mis-
match between the supply of oxygen and nutri-
ents and the metabolic demand of tissues is criti-
cal also at rest, and rest pain and trophic lesions
appear. CLI patients also develop microcirculato-
ry defects including endothelial dysfunction, al-
tered hemorheology, white blood cell activation
and inflammation, and maldistribution of the cu-
taneous microcirculation. The term CLI should
be used only for patients with chronic ischemic
disease, defined as symptoms present for more
than 2 weeks (chronic ischemic rest pain, ulcers
or gangrene) and attributable to objectively
proven arterial occlusive disease, setting off a
cascade of pathophysiologic events that ultimate-
ly lead to the typical severe symptoms. Thus, the
term CLI implies chronicity and is considered
the “end stage” of PAD3-5. CLI is characterized
by a poor long-term prognosis: 1 year after diag-
nosis major limb amputation is required in 30%
of CLI patients, while overall mortality at 1 years
is 25%1, at 5 years is around 50% and at 10 years
it raises to 70%. The morbidity and mortality sur-
rounding bypass surgery is also considerable,
with up to 3% perioperative mortality and a mor-
tality rate at 1 year approaching 20%2. Thus, the
prognosis of CLI patients is similar to that of
some malignancies.
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The primary goals of the treatment are to relieve
ischemic pain, heal (neuro)ischemic ulcers, prevent
limb loss, improve patient function and quality of
life, and, primarily, prolong their survival. Revascu-
larization could optimally achieve some of these
goals, but the severity of comorbidities, along with
durability of the reconstruction in patients with
CLI, demands a risk-benefit analysis to determine
the optimal therapy. Some patients who present to
vascular surgeons for surgical or endovascular pro-
cedures are poor candidates for such procedures be-
cause of medical comorbidities, nonambulatory sta-
tus, or poor outflow vessels in the limb4. Medical
management of CLI includes aggressive modifica-
tion of cardiovascular risk factors, control of pain
and infection in the ischemic leg, prevention of pro-
gression of the systemic atherosclerosis, and opti-
mization of cardiac and respiratory function5. The
only pharmacotherapy for CLI recommended by
current guidelines in patients unsuitable for revas-
cularization is represented by prostanoids, the only
drugs that showed consistent evidence in improving
ischemic symptoms1,6,7. The synthetic prostacyclin
analogue iloprost closely mimics the whole range
of endogenous prostacyclin’s physiological effects,
restoring the altered microcirculation by inducing
vasodilation, inhibiting platelet activation, repairing
and protecting the endothelium, activating the en-
dogenous fibrinolysis and correcting cytokine im-
balances8. The effects of iloprost are mediated by
its specific binding to PGI2 receptors (IP receptors)
with subsequent increase in intracellular cAMP lev-
els, but also PPARs activation was described, indi-
cating a modulation of the expression of many
genes (i.e. VEGF, TGF-beta, CTGF, MCP-1, PAI-
1)9-14, contributing to the explanation of the wide
and long lasting effects of the drug15. Also, in an-
other study where iloprost has been used for the
treatment of patients with CLI, the authors have
documented the further potential of the drug to in-
crease significantly the number of circulating en-
dothelial progenitor cells16. 
Several studies have shown that therapy with
prostanoids may have a favorable impact on mor-
tality and amputation rates, but usually follow-up
was conducted for a maximum period of 1
year17,18, so that we do not know yet the real ef-
fect of this therapy on long-term follow-up.
In the present study, a large number of consec-
utive CLI patients with long-term follow-up was
assessed, with the aim to describe and identify:
risk factors, morbidity and complications, predic-
tors, mortality rates, causes of death, and pharma-
cotherapy response.
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Patients and methods
Case-control, retrospective study conducted in
accordance with the Declaration of Helsinki ad
current ethical standards, which included 181
CLI patients, consecutively admitted to different
medical and surgical wards of the University
Hospital of Pisa, Italy.
The inclusion criterion was the clinical and in-
strumental diagnosis of critical ischemia of the
lower limbs. The instrumental evaluations in-
cluded transcutaneous tensiometry of oxygen
(TcpO2) and carbon dioxide (TcpCO2). Ultra-
sound examinations and angiography of the low-
er extremities were performed in all patients to
confirm the diagnosis. In the years after diagno-
sis, all patients underwent repeated clinical and
instrumental examinations.
The data used in this study were obtained from
medical records of patients. All patients and/or
their families (and possibly family doctors) were
contacted by telephone with an invitation for pa-
tients undergo a new visit. In case of death, the
certificates were collected.
The data collected included demographic and
clinical characteristics, concomitant and previous
diseases, major and minor amputations, compli-
cations of CLI, mortality rates, causes of death,
and administered treatments.
Statistical Analysis 
The differences between categorical and contin-
uous variables were calculated using ANOVA and
the χ-square test, respectively. The statistical asso-
ciations were calculated using multivariate logistic
regression using the status in life as a binary vari-
able (coded as 0 and 1). Descriptive statistics were
the mean ± standard deviation (SD) or median for
data in non-normal distribution. Statistical signifi-
cance was considered at p values <0.05.
Results
Characteristics of patients
Table I shows the baseline demographic and
clinical characteristics of the study population.
The minimum duration of follow-up was 5 years
and the maximum period was up to 15 years.
Globally, a high average age of the patients, a high
prevalence of Fontaine stage IV arteriopathy, and
a high positive anamnesis for major known car-
dio- and cerebro-vascular risk factors and/or
events were reported.
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Risk factors
Arterial hypertension was the only known risk
factor, among those evaluated, significantly and
negatively correlated with the survival of patients
included in the study (p<0.01). Overall, in this
study, the diabetic patients had a prognosis simi-
lar to that of non-diabetics.
Pharmacological therapy
Following the diagnosis of CLI, all patients un-
derwent the best possible therapy, which, in the
first instance, included surgical and/or endovascu-
lar revascularization (19%), and, when it was un-
feasible in the immediate or ever, patients received
pharmacological treatment with i.v. iloprost ad-
ministered at the rate of 0.5-2 ng/kg/min for 6
hours/day for 2-4 weeks (repeating the administra-
tion regimen regularly in time every six months in
case of favourable clinical and instrumental re-
sponses), or alternative therapy (sympathicolysis
in 3%, electrical chronic spinal cord stimulation in
6%).
Overall, iloprost was used in 46% (n = 84) of
patients (Table II) and the characteristics of the
treated and untreated population at baseline were
similar. The medically treated and untreated pa-
tients showed statistically significant differences in
terms of 5-year survival (69% vs. 47%, p<0.0001),
major amputation (6% vs. 21%, p<0.0001), subse-
quent vascular surgery (4% vs. 32%, p<0.0001)
(Figure 1 and Table II). In addition, a reduced
number, although not statistically significant, of
minor amputations was observed in patients who
received iloprost (7% vs. 12%).
The other drugs administered to patients includ-
ed antiplatelet agents (a total of 74% of patients),
anti-hypertensives, nitrocompounds, oral antico-
agulants, and statins, whose use was homoge-
neous among the different groups of patients and
was not associated with significant differences in
survival.
Survival and amputations
Figure 1 shows survival curves of total CLI
population and patients treated or not treated with
iloprost. The overall curve confirms the poor
prognosis of CLI patients: mortality in long-term
follow-up reaches 15% after 1 year, 24% after 2
years, and 43% after 5 years.
Figure 2 shows the rates of major and minor
amputations, of total deaths and the causes of
death, represented by cardio- and/or cerebro-vas-
cular events in the large majority of cases.
In the 25 observed amputees, transcutaneous
oximetry, measured in the supine (median 0
mmHg, p<0.0019) and dependent positions (medi-
an 3 mmHg, p<0.00001), and transcutaneous cap-
nometry, assessed in the supine (median 83
mmHg, p<0.00001) and dependent positions (me-
dian 53 mmHg, p<0.0011) were significantly re-
lated to the risk of major amputation.
Discussion
Our study confirms the poor prognosis of CLI
patients, since the overall mortality rate amounted
Male 56 % (n=101)
BMI (kg/m2) ± SD 25 ± 3
Age (years) 72±10
Fontaine stage III 28 % (n=50)
Fontaine stage IV 72 % (n=131)
Diabetes mellitus 55 % (n=100)
Hypercholesterolemia 75 % (n=136)
Hypertension 68 % (n=123)
Current smokers 45% (n=81)
Ex smokers 14% (n=25)
CAD 37 % (n=67)
AMI 18 % (n=33)
AF 6 % (n=12)
COPD 7 % (n=13)
Stroke 14 % (n=26)
CVD 23 % (n=42)
Cancer 12 % (n=22)
Previous procedures:
Vascular surgery 31 % (n=57)
Sympathicolysis 7 % (n=12)
SCS 6 % (n=10)




Supine mmHg (range) 0 (0-46)
Dependent mmHg (range) 29 (0-72)
Median TcpCO2
Supine mmHg (range) 44 (35-175)
Dependent mmHg (range) 39 (34-135)
Contralateral limb
Median TcpO2
Supine mmHg (range) 38 (0-73)
Dependent mmHg (range) 51 (0-87)
Median TcpCO2
Supine mmHg (range) 38 (35-110)
Dependent mmHg (range) 37 (34-100)
Table I. Demographic and clinical characteristics of the total
population (n=181).
SBP: Systolic blood pressure; DBP: Diastolic blood pres-
sure; PP: Partial pressure; CAD: Coronary artery disease;
AMI: Acute myocardial infarction; AF: Atrial fibrillation;
COPD: Chronic obstructive pulmonary disease; CVD: Cere-
bral vascular disease; SCS: Spinal cord stimulation.
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to 15% after 1 year, 24% after 2 years and 43% af-
ter 5 years. However, the mortality rate of 15% at
one year is lower than the rate at 1 year according
to the natural history of disease (25%1), which is
reached only on the second year of follow-up, tes-
tifying effectiveness of our overall therapeutic ap-
proach. As expected for patients suffering from
CLI, the main causes of death were due to cardio-
and/or cerebro-vascular events.
In the 181 CLI patients included in this study,
the transcutaneous measurements in symptomatic
forefoot provided a markedly image of the severe
metabolic damage caused by ischemia.
Overall, 14% of patients underwent major am-
putation, despite the administered therapies, con-
firming the poor prognosis described in the liter-
ature1. 
The importance of an immediate approach to a
vascular specialist who can address the early CLI
patient to the best possible treatment was empha-
sized by the studies of Dormandy et al19,20 which
reported that in about 30% of the cases the major
Figure 1. Survival curves of
total sample (n=181) and pa-
tients treated (n=84) or not treat-
ed (n=97) with iloprost.
Years
%
Iloprost (n=84) Non-Iloprost (n=97) p-value
Age (years) ± SD 74 ± 6 71 ± 7 NS
Diabetes mellitus 52% (n=44) 39% (n=38) NS
Hypertension 64% (n=54) 69% (n=67) NS
Fontaine stage III 30% (n=25) 26% (n=25) NS
Fontaine stage IV 70% (n=59) 74% (n=72) NS
Previous procedures
Vascular surgery 30% (n=25) 33% (n=32) NS
Sympathicolysis 1% (n=1) 11% (n=11) NS
SCS 12% (n=10) 0% (n=0) <0.05
Contralateral amputation 1% (n=1) 3% (n=3) NS
Subsequent procedures
Major amputations 6% (n=5) 21% (n=20) <0.00001
Minor amputations 7% (n=6) 12% (n=12) NS
Vascular surgery 4% (n=3) 32% (n=31) <0.00001
Sympathicolysis 0% (n=0) 5% (n=5) NS
SCS 1% (n=1) 7% (n=7) <0.05
Survival:
1 year 86% (n=72) 84% (n=81) NS
2 years 80% (n=67) 73% (n=71) NS
5 years 69% (n=58) 47% (n=46) <0.0001
Table II. Characteristics and outcomes of patients treated or not treated with iloprost.
SCS: Spinal cord stimulation
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amputation of the symptomatic limb is performed
without the evaluation of a vascular surgeon.
Similar considerations have been formulated by
Abou-Zamzam et al21 who point out that a quarter
of CLI patients arrive at the vascular surgeon, in
the presence of an extended limb gangrene or in-
fection, symptoms that prevent limb salvage.
In the present study, all patients after diagnosis
of CLI, have been subjected to the best possible
treatment, represented, first, by revascularization
surgery and/or endovascular treatment, when ap-
propriate. Only 19% of patients has been subject-
ed to such treatment, that is a lower value com-
pared to that of patients theoretically operable as
assumed in the literature (about 50%). However,
considering that 31% of patients had undergone
vascular surgery prior to entry into the study, the
proportion of the total population surgically treat-
ed rises to 50%. This number would be even
higher if other interventions such as sympaticoly-
sis or SCS were considered. 
When the vascular intervention was not feasi-
ble, at the time of diagnosis (for concomitant se-
rious comorbidity) or in general (for anatomical
reasons), as suggested by main current guide-
lines, our patients were treated with i.v. iloprost
administered for several weeks, or with alterna-
tive therapies. 
The use of iloprost as prostanoid of choice re-
sults from our favorable experience and the well
documented efficacy reported in the litera-
ture1,15,22,23. In particular, in the meta-analysis of
Loosemore et al22 of 6 RCTs that included 705
Fontaine stage III and IV patients unsuitable for
revascularization, therapy with iloprost for two
to four consecutive weeks showed significant
beneficial effects on ulcer healing, pain relief,
and with regards to the probability of being alive
with both legs at six months of follow-up. More-
over, in another RCT that evaluated the effects of
iloprost and alprostadil, in a group of 267
Fontaine stage IV patients, iloprost showed a
higher responder rate (52.7% vs. 43.1%), a re-
duced number of deaths (7.5% vs. 14.6%), and
similar effects in diabetics and non-diabetics
(53.3% and 51.4% response rates, respectively),
while the diabetics treated with alprostadil had a
considerably poorer outcome (36.6% vs .
53.3%)23.
In addition, in 2010 the meta-analysis of Ruf-
folo et al24 has documented the efficacy of
prostanoids in the treatment of CLI and, in par-
ticular, the favourable use of iloprost in rest pain
relief, in ulcer healing and reduction of major
amputations.
More recently a consensus of the Italian Societes
of Diabetes, Radiology and Vascular Endovascular
Surgery has proposed in diabetic CLI patients the
use of iloprost not as alternative to peripheral revas-
cularization, but in reduction of rest pain before
revascularization or as its pharmacological use after
revascularization, to improve tissue perfusion and
quality of life of patients25.
Overall, in our series, the patients treated with
iloprost, compared with untreated patients,
showed a significant reduction in mortality at 5
years (31% vs. 53%) and major (6% vs. 21%)
and minor (7% vs. 12%) amputations, which rep-
resent the most important endpoints for patients
with CLI. It is noteworthy to emphasize that the
difference in survival rates between the patients
treated and not treated with iloprost is at the fifth
Figure 2. Rates of major and minor amputations, of total deaths and causes of death of the study population (n=181). Key: AMI:
Acute myocardial infarction; HF: Heart failure; PE: Pulmonary embolism; CVD: Cerebrovascular disease.
year of follow-up, that is, at very long-term. So,
if we state the response to iloprost therapy only
immediately or one-six month after treatment,
we cannot fully understand its real clinical effect.
In addition, in CLI patients treated with ilo-
prost, the subsequent vascular surgery procedures
were also reduced (4% vs. 32%), indicating a sta-
bilization of the clinical picture, with a lower
need of performing further procedures. These are
hard and clinically relevant outcomes. Our data
show, therefore, that iloprost resulted in a signifi-
cant clinical benefit both locally, as expected, and
primarily systemically in terms of reduction of
cardiovascular mortality and morbidity in very
long-term follow-up. Prostanoids mainly act on
adaptive metabolic capacities to ischemia and, so
far, iloprost is the only pharmacological agent
that has been convincingly shown to have a posi-
tive influence on the prognosis of CLI patients.
Thus, without being an alternative to revascu-
larization, iloprost should be used: in every pa-
tient unsuitable for revascularization, in every
patient suitable for revascularizations as adjuvant
therapy (both pre-and post-operatively, using dif-
ferent infusion schemes), preferentially in the
early stages of critical ischemia, when the dam-
age is limited and not irreversible and in CLI pa-
tients who cannot be revascularized immediately,
because of the limited prospects of success3,26-28.
Althoug it is a retrospective design and the
analysis of data are extracted from medical
records, the authors believe that these results can
be considered reliable, as complete informations
were recovered for each patient. In addition, our
findings are consistent with previous randomized
trials and observational data in the literature, indi-
cating the poor prognosis of CLI patients, and the
role of risk factors and drug treatment, particularly
with iloprost. In the future, it will be necessary to
confirm our results through the collection of infor-
mation in prospective multicenter registries.
Conclusions 
Our study confirms the poor prognosis of CLI
patients and shows the correlation between im-
portant clinical endpoints, such as amputation
rates and overall mortality, and cardiovascular
risk factors and pharmacological treatment in a
very long-term follow-up. In particular, iloprost
administration is associated with an overall better
clinical outcome in a real life setting, confirming
previous evidence in the literature. 
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